BCL-2 is dispensable for thrombopoiesis and platelet survival
BCL-2 is dispensable for thrombopoiesis and platelet survival
About this item
Full title
Author / Creator
Debrincat, M A , Pleines, I , Lebois, M , Lane, R M , Holmes, M L , Corbin, J , Vandenberg, C J , Alexander, W S , Ng, A P , Strasser, A , Bouillet, P , Sola-Visner, M , Kile, B T and Josefsson, E C
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-X
L
and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on B...
Alternative Titles
Full title
BCL-2 is dispensable for thrombopoiesis and platelet survival
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4650559
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4650559
Other Identifiers
ISSN
2041-4889
E-ISSN
2041-4889
DOI
10.1038/cddis.2015.97
